Information Provided By: 
Fly News Breaks for May 8, 2015
FLML
May 8, 2015 | 08:53 EDT
After Jazz Pharmaceuticals (JAZZ) and Concert (CNCE) announced that Phase 1 PK/PD results for their JZP-386 drug do not support advancing the candidate into later-stage development at this time, JMP Securities says the news is positive for Flamel (FLML). The firm says that Flamel's competing drug candidate appears to be the most advanced of its kind in the market. JMP Securities is upbeat on the outlook for Flamel's drug and keeps an Outperform rating on the shares.
News For FLML From the Last 2 Days
There are no results for your query FLML
